Literature DB >> 9536320

Treatment of osteoporosis with vitamin D.

J A Kanis1, E V McCloskey, D de Takats, J Bernard, D M Zhang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9536320     DOI： 10.1007/bf03194360

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  46 in total

1.  Prevention of post-menopausal bone loss with 1 alpha-hydroxy vitamin D3. A three-year prospective study.

Authors:  J M Pouilles; F Tremollieres; C Ribot
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

2.  Influence of age and body mass on the effects of vitamin D on hip fracture risk.

Authors:  J Ranstam; J A Kanis
Journal:  Osteoporos Int       Date:  1995       Impact factor: 4.507

3.  Plasma creatinine and creatinine clearance in nutritional osteomalacia.

Authors:  V Fonseca; J Mohiuddin; J Weerakoon; M Boss; D P Mikhailidis; P Dandona
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

4.  Effects of vitamin D metabolites and analogues on renal function.

Authors:  R B Naik; T Cundy; B H Robinson; R G Russell; J A Kanis
Journal:  Nephron       Date:  1981       Impact factor: 2.847

Review 5.  Vitamin D deficiency and osteoporosis: the role of vitamin D deficiency and treatment with vitamin D and analogues in the prevention of osteoporosis-related fractures.

Authors:  P Lips
Journal:  Eur J Clin Invest       Date:  1996-06       Impact factor: 4.686

6.  Calcitriol in the treatment of postmenopausal osteoporosis.

Authors:  J F Aloia; A Vaswani; J K Yeh; K Ellis; S Yasumura; S H Cohn
Journal:  Am J Med       Date:  1988-03       Impact factor: 4.965

7.  Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3.

Authors:  H Orimo; M Shiraki; T Hayashi; T Nakamura
Journal:  Bone Miner       Date:  1987-10

8.  Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1, 24 Dihydroxycholecalciferol (1, 24(OH)2D3).

Authors:  M Shiraki; H Orimo; H Ito; I Akiguchi; J Nakao; R Takahashi; S Ishizuka
Journal:  Endocrinol Jpn       Date:  1985-04

9.  Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.

Authors:  N A Hamdy; J A Kanis; M N Beneton; C B Brown; J R Juttmann; J G Jordans; S Josse; A Meyrier; R L Lins; I T Fairey
Journal:  BMJ       Date:  1995-02-11

10.  Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis.

Authors:  H Orimo; M Shiraki; Y Hayashi; T Hoshino; T Onaya; S Miyazaki; H Kurosawa; T Nakamura; N Ogawa
Journal:  Calcif Tissue Int       Date:  1994-05       Impact factor: 4.333
View more
  3 in total

1.  Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes.

Authors:  M L Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2010-09

2.  Osteoporosis Update 1997. Symposium proceedings. Osaka, Japan, 13-16 November 1997.

Authors: 
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis.

Authors:  S A Brown; D A Ontjes; G E Lester; R K Lark; M B Hensler; A D Blackwood; M J Caminiti; D C Backlund; R M Aris
Journal:  Osteoporos Int       Date:  2003-05-28       Impact factor: 4.507
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.